Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  Sato, Akinori ^a   Asano, Takako ^a   Isono, Makoto ^a   To, Keiichi ^a   Asano, Tomohiko ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Bortezomib; Combination therapy; Endoplasmic reticulum stress; Histone acetylation; Panobinostat; Renal cancer; Ubiquitinated protein

Indexed keywords

ALPHA TUBULIN; BORTEZOMIB; PANOBINOSTAT; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; PYRAZINE DERIVATIVE; UBIQUITINATED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CELLULAR DISTRIBUTION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; HISTONE ACETYLATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN UNFOLDING; RENAL CANCER CELL LINE; UBIQUITINATION; ACETYLATION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; HUMAN; KIDNEY NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; INDOLES; KIDNEY NEOPLASMS; MICE, INBRED BALB C; PYRAZINES; UBIQUITINATED PROTEINS;

EID: 84925234997     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-71     Document Type: Article

References (23)

1. Liu Y, Ye Y: Proteostasis regulation at the endoplasmic reticulum: A new perturbation site for targeted cancer therapy. Cell Res 2011, 21:867-883.
2. Tabas I, Ron D: Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011, 13:184-190.
3. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004, 3:551-566.
4. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280:26729-26734.
5. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82:373-428.
6. Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM: Panobinostat activity in both bexarotene-exposed and-naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013, 49:386-394.
7. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S: Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012, 53:1820-1823.
8. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y: Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs 2012, 30:1950-1957.
9. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA: A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest 2011, 29:451-455.
10. Kane RC, Farrell AT, Sridhara R, Pazdur R: United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006, 12:2955-2960.
11. Jiang XJ, Huang KK, Yang M, Qiao L, Wang Q, Ye JY, Zhou HS, Yi ZS, Wu FQ, Wang ZX, Zhao QX, Meng FY: Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-?B pathways. Cancer Lett 2012, 326:135-142.
12. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN: Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res 2010, 16:4742-4754.
13. Sato A, Asano T, Ito K, Sumitomo M, Asano T: Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int 2012, 109:1258-1268.
14. Mori K: Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000, 101:451-454.
15. Lee AS: The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005, 35:373-381.
16. Gupta S, Deepti A, Deegan S, Lisbona F, Hetz C, Samali A: HSP72 protects cells from ER stress-induced apoptosis via enhancement of IRE1alpha-XBP1 signaling through a physical interaction. PLoS Biol 2010, 8:e1000410.
17. Mezghrani A, Fassio A, Benham A, Simmen T, Braakman I, Sitia R: Manipulation of oxidative protein folding and PDI redox state in mammalian cells. EMBO J 2001, 20:6288-6296.
18. Bulleid NJ, Freedman RB: Defective co-Translational formation of disulphide bonds in protein disulphide-isomerase-deficient microsomes. Nature 1988, 335:649-651.
19. Anelli T, Alessio M, Mezghrani A, Simmen T, Talamo F, Bachi A, Sitia R: ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin family. EMBO J 2002, 21:835-844.
20. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP: HDAC6 is a microtubule-Associated deacetylase. Nature 2002, 417:455-458.
21. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002, 99:14374-14379.
22. Sato A, Asano T, Ito K, Asano T: Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. J Urol 2012, 188:2410-2418.
23. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S: PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013, 122:2331-2337.